R&D News | pharmaphorum

News

Lilly trumpets heart health data with Mounjaro

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

News

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

Tidmarsh to stand in for Prasad's role at CBER

Following Vinay Prasad's abrupt departure as CBER director, FDA has asked CDER head George Tidmarsh to take on both roles while a successor is sought.

News

GSK suffers a setback with its TIM-3 programme

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.

News

White House retreats from block on NIH research funding

A move by the Trump administration to block NIH research funding for external research teams appears to have been abandoned.

News

Vinay Prasad abruptly departs from the FDA

The disruption at the FDA continues with the departure of CBER director Vinay Prasad, less than three months after taking on the role.

Lilly trumpets heart health data with Mounjaro

Is AbbVie planning an epic Gilgamesh takeover?

Tidmarsh to stand in for Prasad's role at CBER

GSK suffers a setback with its TIM-3 programme

White House retreats from block on NIH research funding

Vinay Prasad abruptly departs from the FDA

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

News

Editor's Picks